加拿大 - 英文 - Health Canada

hill dermaceuticals inc - fluocinolone acetonide - solution - 0.01% - fluocinolone acetonide 0.01% - corticosteroids

加拿大 - 英文 - Health Canada

bausch & lomb inc - fluocinolone acetonide - implant - 0.59mg - fluocinolone acetonide 0.59mg - corticosteroids

美国 - 英文 - NLM (National Library of Medicine)

arbor pharmaceuticals - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u), fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - ciprofloxacin 872.5 ug in 0.25 ml - otovel is indicated for the treatment of acute otitis media with tympanostomy tubes (aomt) in pediatric patients (aged 6 months and older) due to staphylococcus aureus, streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, and pseudomonas aeruginosa . otovel is contraindicated in: - patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of otovel. - viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections. risk summary otovel is negligibly absorbed following otic administration and maternal use is not expected to result in fetal exposure to ciprofloxacin and fluocinolone acetonide [see clinical pharmacology (12.3) ]. risk summary otovel is negligibly absorbed by the mother following otic administration and breastfeeding is not expected to result in exposure of the infant to ciprofloxacin and fluocinolone acetonide [see clinical phar

加拿大 - 英文 - Health Canada

knight therapeutics inc. - fluocinolone acetonide - implant - 0.19mg - fluocinolone acetonide 0.19mg - corticosteroids

美国 - 英文 - NLM (National Library of Medicine)

medimetriks pharmaceuticals, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - synalar® solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

美国 - 英文 - NLM (National Library of Medicine)

medimetriks pharmaceuticals, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - synalar® ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

美国 - 英文 - NLM (National Library of Medicine)

zoetis inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m), dimethyl sulfoxide (unii: yow8v9698h) (dimethyl sulfoxide - unii:yow8v9698h) - synotic otic solution veterinary is indicated for the relief of pruritus and inflammation associated with acute and chronic otitis in the dog.

美国 - 英文 - NLM (National Library of Medicine)

wraser llc - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u), fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - otovel is indicated for the treatment of acute otitis media with tympanostomy tubes (aomt) in pediatric patients (aged 6 months and older) due to staphylococcus aureus , streptococcus pneumoniae , haemophilus influenzae , moraxella catarrhalis , and pseudomonas aeruginosa . otovel is contraindicated in: - patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of otovel. - viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections. risk summary otovel is negligibly absorbed following otic administration and maternal use is not expected to result in fetal exposure to ciprofloxacin and fluocinolone acetonide [see clinical pharmacology (12.3)]. risk summary otovel is negligibly absorbed by the mother following otic administration and breastfeeding is not expected to result in exposure of the infant to ciprofloxacin and fluocinolone acetonide [ see clinical pharmacology (12.3) ]. otovel has been studied in patients as young as 6 months in adequate and well-controlled clinical trials. no major differences in safety and effectiveness have been observed between adult and pediatric patients [ see indications and usage (1)and dosage and administration (2)]. clinical studies of otovel did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. read this instructions for use that comes with otovel before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your healthcare provider about your medical condition or treatment. important information about otovel : - otovel is for use in the ear only (otic use) . do not inject otovel or use otovel in the eye. - use otovel solution exactly as your healthcare provider tells you to use it. how should i use otovel? this instructions for use has been approved by the food and drug administration.

美国 - 英文 - NLM (National Library of Medicine)

alimera sciences, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - yutiq® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. yutiq is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases. yutiq is contraindicated in patients with known hypersensitivity to any components of this product. risk summary adequate and well-controlled studies with yutiq have not been conducted in pregnant women to inform drug associated risk. animal reproduction studies have not been conducted with yutiq. it is not known whether yutiq can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage leve

新加坡 - 英文 - HSA (Health Sciences Authority)

galderma singapore private limited - fluocinolone acetonide; hydroquinone; tretinoin - cream - 0.1 mg/g - fluocinolone acetonide 0.1 mg/g; hydroquinone 40 mg/g; tretinoin 0.5 mg/g